| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/22/2013 | US20130217616 Chimeric inhibitor molecules of complement activation |
| 08/22/2013 | US20130217615 Combination treatment of major depressive disorder |
| 08/22/2013 | US20130217129 Conditioned cell culture medium compositions and methods of use |
| 08/22/2013 | US20130217069 Conditioned cell culture medium compositions and methods of use |
| 08/22/2013 | US20130216625 Treatment of insulin resistance or diseases associated with insulin resistance |
| 08/22/2013 | US20130216622 Modified beta-lactamases and methods and uses related thereto |
| 08/22/2013 | US20130216620 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 08/22/2013 | US20130216615 Pharmaceutical Compositions Containing Dimethyl Fumarate |
| 08/22/2013 | US20130216592 Particles consisting of a chitosan polyelectrolyte complex and of an anionic polysaccharide, and having improved stability |
| 08/22/2013 | US20130216577 Methods And Compositions For The Dietary Management Of Autoimmune Disorders |
| 08/22/2013 | US20130216558 Compositions and methods for treating haematological proliferative disorders of myeloid origin |
| 08/22/2013 | US20130216552 Crth2 modulators |
| 08/22/2013 | US20130216548 Monoclonal antibodies against c-met |
| 08/22/2013 | US20130216546 Methods of Treating Glucose Metabolism Disorders |
| 08/22/2013 | US20130216533 Biological markers for identifying patients for treatment with vegf antagonists |
| 08/22/2013 | US20130216527 Novel anti-cmet antibody |
| 08/22/2013 | US20130216508 Human lung stem cells and uses thereof |
| 08/22/2013 | US20130216498 Imidazopyridine derivatives as jak inhibitors |
| 08/22/2013 | US20130216497 Novel tricyclic compounds |
| 08/22/2013 | US20130216496 Methods for treating tweak-related conditions |
| 08/22/2013 | US20130216474 Nanocells for diagnosis and treatment of diseases and disorders |
| 08/21/2013 | EP2628488A1 Sustained-release pharmaceutical composition |
| 08/21/2013 | EP2628487A1 Adjuvant composition for topical use |
| 08/21/2013 | EP2627665A1 Methods and compositions for treating hemophilia b |
| 08/21/2013 | EP2627334A1 Methods and compositions for inhibition of polymerase |
| 08/21/2013 | EP2627328A1 Combinations of serotonin receptor agonists for treatment of movement disorders |
| 08/21/2013 | EP2627325A1 Pharmaceutical composition |
| 08/21/2013 | EP2627193A1 Yeast-derived feed additive |
| 08/21/2013 | CN103261413A Marker for determination of sensitivity to triplet combination anti-cancer agent |
| 08/21/2013 | CN103260584A Dye composition having low content of ammonia |
| 08/21/2013 | CN103254129A Intergrase inhibitor |
| 08/21/2013 | CN103251954A Diabetes treating compound medicine for reducing side effect of rosiglitazone and preparation method thereof |
| 08/21/2013 | CN103251953A Flt3 inhibitors for immune suppression |
| 08/21/2013 | CN103251952A Genetic products differentially expressed in tumors and use thereof |
| 08/21/2013 | CN103251951A Application of P2X2 receptor agonist or opening agent in preparation of anti-depression or anti-anxiety drugs |
| 08/21/2013 | CN103251950A Use of S1P receptor conditioning agent on preventing and curing intestinal radiation sickness and radiation enteritis |
| 08/21/2013 | CN103251647A Methods for treating bleeding disorders using sulfated polysaccharides |
| 08/21/2013 | CN103251627A Application of carbenoxolone or salt thereof in preparation of medicine for treating inflammatory diseases |
| 08/21/2013 | CN103251581A Application of ampelopsin in mutation resistance composition preparation |
| 08/21/2013 | CN103251573A Protein micro/nano sphere carrying antitumor chemotherapeutic medicine and preparation method of protein micro/nano sphere |
| 08/21/2013 | CN103251571A Potassium ion binding polymers for pharmaceutical compositions |
| 08/21/2013 | CN103251561A Double-sensitive disintegrating nano-sized vesica medicine carrier preparation and preparation method thereof |
| 08/21/2013 | CN102114000B Co-feeding lipid nano-delivery system for medicine carrying |
| 08/21/2013 | CN101935673B siRNA for inhibiting mouse gamma -GABA transfer protein subtype 1 |
| 08/21/2013 | CN101917983B Composition for treating sterile inflammation |
| 08/21/2013 | CN101766549B Combination of monosaccharides and desquamating agents, and use thereof |
| 08/21/2013 | CN101754774B Synergistic combinations of VR-1 antagonists and COX-2 inhibitors |
| 08/21/2013 | CN101664553B Stabilization of hypoxia inducible factor (HIF) alpha |
| 08/21/2013 | CN101663030B Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance |
| 08/20/2013 | US8513281 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 08/20/2013 | US8513237 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 08/20/2013 | US8513198 Pharmaceutical formulation for reducing pain |
| 08/20/2013 | US8513191 Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases |
| 08/20/2013 | US8513190 Method of regulating glucose metabolism, and reagents related thereto |
| 08/20/2013 | US8513027 Method of identifying an inhibitor of the prostanoid EP4 receptor |
| 08/20/2013 | US8512754 Stabilized products, processes and devices for preparing the same |
| 08/20/2013 | US8512723 Decontamination of vegetables, meats or fruits by disinfection of such with antimicrobial solution containing lipid and enhancer such as bacteriocins, sugars and enzymes |
| 08/20/2013 | US8512718 Pharmaceutical composition for topical application |
| 08/20/2013 | US8512690 Derivatised proline containing peptide compounds as protease inhibitors |
| 08/20/2013 | CA2545503C Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 08/20/2013 | CA2487824C Oncolytic viruses as phenotyping agents for neoplasms |
| 08/15/2013 | WO2013120086A1 Inhibition of the glycine cleavage system for treatment of cancer |
| 08/15/2013 | WO2013119870A1 Compositions and methods for treatment of peripheral vascular disease |
| 08/15/2013 | WO2013119304A2 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
| 08/15/2013 | WO2013118126A1 Ladostigil therapy for immunomodulation |
| 08/15/2013 | US20130211368 Microfabricated nanopore device for sustained release of therapeutic agent |
| 08/15/2013 | US20130210888 Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 |
| 08/15/2013 | US20130210887 Dendrimers as non-viral vehicles for gene therapy |
| 08/15/2013 | US20130210874 Dual-acting antihypertensive agents |
| 08/15/2013 | US20130210858 Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists |
| 08/15/2013 | US20130210851 Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative |
| 08/15/2013 | US20130210850 Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
| 08/15/2013 | US20130210842 Pure erlotinib |
| 08/15/2013 | US20130210832 1h-imidazo[4,5-c]quinolines |
| 08/15/2013 | US20130210829 Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| 08/15/2013 | US20130210824 Substituted fused imidazoles and pyrazoles and use thereof |
| 08/15/2013 | US20130210819 Quinazoline derivatives |
| 08/15/2013 | US20130210809 Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| 08/15/2013 | US20130210807 Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. |
| 08/15/2013 | US20130210805 Quinazolinone-type compounds as crth2 antagonists |
| 08/15/2013 | US20130210798 Soluble guanylate cyclase activators |
| 08/15/2013 | US20130210797 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension |
| 08/15/2013 | US20130210795 Substituted dicyanopyridines and use thereof |
| 08/15/2013 | US20130210787 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity |
| 08/15/2013 | US20130210786 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
| 08/15/2013 | US20130210785 Progesterone analogs and uses related thereto |
| 08/15/2013 | US20130210783 Neuroactive steroid compositions and methods of use therefor |
| 08/15/2013 | US20130210778 Formulation for the prevention of cardiovascular disease |
| 08/15/2013 | US20130210774 Potent and selective inhibitors of hepatitis c virus |
| 08/15/2013 | US20130210755 Methods for inhibiting insect infestations |
| 08/15/2013 | US20130210739 Bhlh proteins and their use as drugs |
| 08/15/2013 | US20130210733 Methods of treating lung disease |
| 08/15/2013 | US20130210731 Compositions and methods to control angiogenesis with cupredoxins |
| 08/15/2013 | US20130210725 Conditioned cell culture medium compositions and methods of use |
| 08/15/2013 | US20130210721 Novel 3-hydroxyisothiazole 1-oxide derivatives |
| 08/15/2013 | US20130210720 Treatment of heart failure |
| 08/15/2013 | US20130210719 Treatment of heart failure |
| 08/15/2013 | US20130210718 Biomarkers for Cardiodiabetes |
| 08/15/2013 | US20130210136 Methods For Treating Cardio Pulmonary Diseases With NO Group Compounds |
| 08/15/2013 | US20130210116 Composition and methods for the diagnosis and treatment of tumor |